Bookmark this page you may want it.
Are you worried that you have been exposed to someone carrying coronavirus?
Why not consider taking part in a COVID-19 prevention clinical trial?
If you think your job or living circumstances has exposed you to someone who has tested positive for coronavirus, you may be able to take part in a COVID-19 clinical research study.
You will have access to no-cost study-related care from local doctors. You also will be contributing to the advancement of COVID-19 prevention research. All study-related care will be provided at no cost to you.
Visit http://www.c19STORMCHASERstudy.com to see if you are eligible (This link is for US residents.
For BartHealth (East London) area please email email@example.com
Here is a British website
Barts Health London, United Kingdom, EC1A 7BE
UCLH London, United Kingdom, NW1 2BH
Manchester, United Kingdom, M8 5RB
Wakefield, United Kingdom, WF1 5RH
The other sites are within the USA https://clinicaltrials.gov/ct2/show/NCT04625972
The bit below is wrttten by me and not from the STORMCHASER Team.
I have checked with the person doing the study and having MS and being on MS treatment should not exclude you from this study (if in doubt speak to your MS team and if you participate in the trial let them know)
If you have someone in your family who is infected and you may be at risk from catching the virus, you can get a shot of antibodies and this may stop you getting infected. This is a trial and essentially gives you an instant anti-COVID-19 response in a few minutes.
Can’t make antibodies to SARS-CoV-2? No problem get designer ones. When you get infected your body makes antibodies and this can help get rid of the viral infected cells importantly they can neutralize the viral particles from causing any more infection.
You may be able to take part if you:
• are 18 years of age or older
• do not have a previously confirmed diagnosis of COVID-19
• have, in the past 8 days, been in contact with, or living in
the same residence as, someone who is confirmed to be
infected with SARS-CoV-2 (the virus that causes COVID-19)
The idea of the COVID-19 vaccine is to make high antibody levels and so if you encounter the virus, there are high levels of antibody that block the virus and stop it from infecting you. Therefore, even if you have been infected it is recommended that you get vaccinated because it boosts a whimpy antibody response into a strong antibody response. Meaning you are less likely to get infected and less likely to therefore to infect someone else.
Some people can’t make antibody responses due to their genetics, their diseases or their treatments. However, it is possible to give them some. We know that if you give therapeutic antibodies they have a half-life of about a month; meaning that in a month about half the amount of antibodies remain. You can design the antibodies so they hang around for longer. So it means you can keep antibodies in your blood longer. Ex-pres Trump had 8g of a similar antibody when he got COVID-19 so it means by the time he is charged with some dodgy dealings later this year…he will still probably having those antibodies floating around his body when he is in court. (For the Trump supporters….lighten up this is just a light-hearted way to show that therapeutic antibodies can hang around). Ocrelizumab will still be active for 4-5 half-lives and this is why you only get it every 6 months. So you can get an anti-COVID-19 shot and this should give you protection form many months
When someone gets infected people make antibodies you can find the B cells that make the antibodies and clone them and then you can make the antibodies and select those that have the best viral inhibiting function. Alternatively you can do this from a mouse that makes human antibodies
A pair of antibodies that neutralize SARS-CoV-2 have been made and are being trialled for protection against COVID.
There are quite a few of them around but the first trials using the antibodies in people who were severely ill and guess what they didn’t work properly. Perhaps not so surprising, because it was probably too late. This is why we are essentially nowhere in having drugs to treat the virus, but you need to give anti-virals early; ideally, you have the antibodies on board before the virus infects you.
With COVID-19 typically you may be asymptomatic for a week then have tens days of mild disease before you go to hospitalisation. There are now a few antibodies that have been approved to be given after infection with the view to stop hospitalization.
There is an antibody designed to hang around for a long time made in the UK that is now being trialled. The idea is to use this antibody to protect people, who cannot make antibodies, like people on certain cancer treatments and will probably be of use for treating people taking anti-CD20 antibodies. However, this also means people on immunosuppressive drugs and we know that fingolimod and ocrelizumab and rituximab blunt vaccine responses, making suboptimal responses. They are doing trials now in the UK and in the US. The quicker they recruit the faster they will know if it works. I am sure the health care workers, with MS and taking MS drugs, would have liked the possibility of protection whilst dealing with infected people. This trial will help show that this is a possibility, it will help give some protection to people who can’t make antibodies
The STORM CHASER Study is exploring a combination of two investigational monoclonal antibodies for the prevention of COVID-19. The study medication is not yet approved by regulatory authorities and can
only be given to people as part of a clinical research study.
There are currently 70 sites including 5 in the UK, others are in the US
BARTS is one of these sites